Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    AGBA

    MCap

    USD77m

    Last close

    USD1.03

    ▲ 0.63 (157.50%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    Sareum Holdings

    MCap

    GBP28m

    Last close

    GBP0.27

    ▲ 6.25 (30.49%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Key opinion leader webinar: Context Therapeutics

Key opinion leader webinar: Context Therapeutics

Context Therapeutics — 4 videos in collection

More on this equity

Context Therapeutics (Nasdaq: CNTX) is a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers. The company’s robust clinical programme for lead candidate onapristone extended release (ONA-XR) comprises three Phase II clinical trials and one Phase Ib/II clinical trial in hormone-driven breast, ovarian and endometrial cancer. ONA-XR is a novel, first-in-class small molecule under development as a potent and specific antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. In this webinar, Context’s team and presenters from the American Association for Cancer Research (AACR) conference discuss the important company results presented at the AACR Annual Meeting 2022.

< Previous
Next >

You may also be interested in these:

Healthcare

Context Therapeutics webinar: Claudin 6 x CD3 bispecific antibody data update

Healthcare

Context Therapeutics: Identification of CTIM-76, a CLDN6xCD3 bi-specific antibody

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free